Blindness risk double in men

Article

Despite the higher rate of prevalence in women, it is men who are more likely to suffer severe vision loss as a result of idiopathic intracranial hypertension (IIH), according to study results published online ahead of print by Neurology.

Despite the higher rate of prevalence in women, it is men who are more likely to suffer severe vision loss as a result of idiopathic intracranial hypertension (IIH), according to study results published online ahead of print by Neurology.

Beau B. Bruce, MD of Emory University, Atlanta, US and colleagues conducted a medical record review of IIH patients (n=721) in three hospitals. Subjects, who underwent neuro-ophthalmologic testing, were segregated for gender (male, n=66; female, n=655) and a statistical comparison was undertaken.

The men included in the study were older and more likely to suffer from sleep apnoea than the women: 37 vs 28 years and 24% vs 4%, respectively. As a first symptom of IIH, men tended to report visual disturbance and women, headaches. At the final follow-up point, mean visual acuity was worse for men than for women. After logistical regression analysis, the researchers determined that the 2.1 times increased chance of men developing severe visual loss when compared with women was correlated to sex.

The team therefore concluded that men are more than twice as likely to sustain severe vision loss, to the extent of being declared legally blind, than women, which may be related to the differences in the symptom profile presented by the different genders.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.